Associated Papers
Polymorphisms of uridine glucuronosyltransferase gene and irinotecan toxicity: low dose does not protect from toxicity.
Tziotou M et al.
Ecancermedicalscience, 2014
Interaction of cigarette smoking and carcinogen-metabolizing polymorphisms in the risk of colorectal polyps.
Fu Z et al.
Carcinogenesis, 2013
Evaluation of the association studies of single nucleotide polymorphisms and hepatocellular carcinoma: a systematic review.
Jin F et al.
Journal of Cancer Research and Clinical Oncology, 2011
Family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A): from Gilbert's syndrome to genetic organization and variability.
Strassburg CP et al.
Archives of Toxicology, 2008
Update on tools for evaluation of uridine diphosphoglucuronosyltransferase polymorphisms.
Argikar UA et al.
Expert Opinion on Drug Metabolism & Toxicology, 2008
Variability and function of family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A).
Strassburg CP et al.
Critical Reviews in Clinical Laboratory Sciences, 2008
Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer.
Fujita K et al.
Cancer Chemotherapy and Pharmacology, 2007
Genetic variability, haplotypes, and htSNPs for exons 1 at the human UGT1A locus.
Thomas SS et al.
Human Mutation, 2006
Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer.
Nagar S et al.
Oncogene, 2006
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Carlini LE et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2005
UDP-glucuronosyltransferase 1A7 genetic polymorphisms are associated with hepatocellular carcinoma in japanese patients with hepatitis C virus infection.
Wang Y et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2004
Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs.
Villeneuve L et al.
The Journal of Pharmacology and Experimental Therapeutics, 2003